In a report released today, David Saxon from Needham maintained a Buy rating on CryoPort, with a price target of $11.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
David Saxon has given his Buy rating due to a combination of factors including CryoPort’s impressive revenue performance in the second quarter of 2025, which surpassed market expectations primarily due to the success of its Life Sciences Services division. Additionally, the company’s management has maintained its revenue guidance for 2025, although there is a belief that these projections might be conservative.
Moreover, CryoPort is making significant progress towards achieving adjusted EBITDA profitability, with expectations to reach this milestone in the latter half of 2025. The company’s robust growth trajectory, strong financial position, and appealing valuation further support the Buy recommendation.
In another report released today, Leerink Partners also upgraded the stock to a Buy with a $16.00 price target.
Based on the recent corporate insider activity of 45 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CYRX in relation to earlier this year.